Histone Deacetylase 10-inhibitor Co-Treatment in Cancer
Histone deacetylase inhibitors (HDACi) are promising anticancer agents and are currently being evaluated in clinical trials. However, due to their unselective action, pan-HDACi exhibit dose-limiting side-effects restricting their full potential in anti-cancer therapy. Therefore, characterization of the molecular function of single HDAC isozymes is of major importance for a targeted therapy with less side-effects. We show that HDAC10 overexpression mediated cell survival and targeting of HDAC10 sensitized tumor cells for cytotoxic drug treatment and it correlates with progression or recurrence of neuroblastoma in vivo. These results demonstrate for the first time that HDAC10 induces an alternative lysosomal-mediated tumor cell death pathway, re-sensitizes cells for cytotoxic drugs and may thus be a novel strategy for neuroblastoma therapy.
Further Information: PDF
DKFZ (German Cancer Research Center, Deutsches Krebsforschungszentrum)
Phone: +49-6221-42 2955
Contact
Dr. Ruth Herzog
Media Contact
All latest news from the category: Technology Offerings
Newest articles
Making diamonds at ambient pressure
Scientists develop novel liquid metal alloy system to synthesize diamond under moderate conditions. Did you know that 99% of synthetic diamonds are currently produced using high-pressure and high-temperature (HPHT) methods?[2]…
Eruption of mega-magnetic star lights up nearby galaxy
Thanks to ESA satellites, an international team including UNIGE researchers has detected a giant eruption coming from a magnetar, an extremely magnetic neutron star. While ESA’s satellite INTEGRAL was observing…
Solving the riddle of the sphingolipids in coronary artery disease
Weill Cornell Medicine investigators have uncovered a way to unleash in blood vessels the protective effects of a type of fat-related molecule known as a sphingolipid, suggesting a promising new…